Cargando…

Evaluation of the interaction between tumor growth factor-β and interferon type I pathways in patients with COVID-19: focusing on ages 1 to 90 years

BACKGROUND: Evidence revealed that age could affect immune responses in patients with the acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) infection. This study investigated the impact of age on immune responses, especially on the interaction between the tumor growth factor-β (TGF-β) and int...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbasifard, Mitra, Fakhrabadi, Ali Hasani, Bahremand, Fatemeh, Khorramdelazad, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112317/
https://www.ncbi.nlm.nih.gov/pubmed/37072722
http://dx.doi.org/10.1186/s12879-023-08225-9
_version_ 1785027602448121856
author Abbasifard, Mitra
Fakhrabadi, Ali Hasani
Bahremand, Fatemeh
Khorramdelazad, Hossein
author_facet Abbasifard, Mitra
Fakhrabadi, Ali Hasani
Bahremand, Fatemeh
Khorramdelazad, Hossein
author_sort Abbasifard, Mitra
collection PubMed
description BACKGROUND: Evidence revealed that age could affect immune responses in patients with the acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) infection. This study investigated the impact of age on immune responses, especially on the interaction between the tumor growth factor-β (TGF-β) and interferon type-I (IFN-I) axes in the pathogenesis of novel coronavirus disease 2019 (COVID-19). METHODS: This age-matched case–control investigation enrolled 41 COVID-19 patients and 40 healthy controls categorized into four groups, including group 1 (up to 20 years), group 2 (20–40 years), group 3 (40–60 years), and group 4 (over 60 years). Blood samples were collected at the time of admission. The expression of TGF-βRI, TGF-βRII, IFNARI, IFNARII, interferon regulatory factor 9 (IRF9), and SMAD family member 3 (SMAD3) was measured using the real-time PCR technique. In addition, serum levels of TGF-β, IFN-α, and SERPINE1 were measured by the enzyme-linked immunosorbent assay (ELISA) technique. All biomarkers were measured and analyzed in the four age studies groups. RESULTS: The expression of TGF-βRI, TGF-βRII, IFNARI, IFNARII, IRF9, and SMAD3 was markedly upregulated in all age groups of patients compared with the matched control groups. Serum levels of IFN-α and SERPINE1 were significantly higher in patient groups than in control groups. While TGF-β serum levels were only significantly elevated in the 20 to 40 and over 60 years patient group than in matched control groups. CONCLUSIONS: These data showed that the age of patients, at least at the time of admission, may not significantly affect TGF-β- and IFN-I-associated immune responses. However, it is possible that the severity of the disease affects these pathway-mediated responses, and more studies with a larger sample size are needed to verify it. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-023-08225-9.
format Online
Article
Text
id pubmed-10112317
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101123172023-04-20 Evaluation of the interaction between tumor growth factor-β and interferon type I pathways in patients with COVID-19: focusing on ages 1 to 90 years Abbasifard, Mitra Fakhrabadi, Ali Hasani Bahremand, Fatemeh Khorramdelazad, Hossein BMC Infect Dis Research BACKGROUND: Evidence revealed that age could affect immune responses in patients with the acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) infection. This study investigated the impact of age on immune responses, especially on the interaction between the tumor growth factor-β (TGF-β) and interferon type-I (IFN-I) axes in the pathogenesis of novel coronavirus disease 2019 (COVID-19). METHODS: This age-matched case–control investigation enrolled 41 COVID-19 patients and 40 healthy controls categorized into four groups, including group 1 (up to 20 years), group 2 (20–40 years), group 3 (40–60 years), and group 4 (over 60 years). Blood samples were collected at the time of admission. The expression of TGF-βRI, TGF-βRII, IFNARI, IFNARII, interferon regulatory factor 9 (IRF9), and SMAD family member 3 (SMAD3) was measured using the real-time PCR technique. In addition, serum levels of TGF-β, IFN-α, and SERPINE1 were measured by the enzyme-linked immunosorbent assay (ELISA) technique. All biomarkers were measured and analyzed in the four age studies groups. RESULTS: The expression of TGF-βRI, TGF-βRII, IFNARI, IFNARII, IRF9, and SMAD3 was markedly upregulated in all age groups of patients compared with the matched control groups. Serum levels of IFN-α and SERPINE1 were significantly higher in patient groups than in control groups. While TGF-β serum levels were only significantly elevated in the 20 to 40 and over 60 years patient group than in matched control groups. CONCLUSIONS: These data showed that the age of patients, at least at the time of admission, may not significantly affect TGF-β- and IFN-I-associated immune responses. However, it is possible that the severity of the disease affects these pathway-mediated responses, and more studies with a larger sample size are needed to verify it. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-023-08225-9. BioMed Central 2023-04-18 /pmc/articles/PMC10112317/ /pubmed/37072722 http://dx.doi.org/10.1186/s12879-023-08225-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Abbasifard, Mitra
Fakhrabadi, Ali Hasani
Bahremand, Fatemeh
Khorramdelazad, Hossein
Evaluation of the interaction between tumor growth factor-β and interferon type I pathways in patients with COVID-19: focusing on ages 1 to 90 years
title Evaluation of the interaction between tumor growth factor-β and interferon type I pathways in patients with COVID-19: focusing on ages 1 to 90 years
title_full Evaluation of the interaction between tumor growth factor-β and interferon type I pathways in patients with COVID-19: focusing on ages 1 to 90 years
title_fullStr Evaluation of the interaction between tumor growth factor-β and interferon type I pathways in patients with COVID-19: focusing on ages 1 to 90 years
title_full_unstemmed Evaluation of the interaction between tumor growth factor-β and interferon type I pathways in patients with COVID-19: focusing on ages 1 to 90 years
title_short Evaluation of the interaction between tumor growth factor-β and interferon type I pathways in patients with COVID-19: focusing on ages 1 to 90 years
title_sort evaluation of the interaction between tumor growth factor-β and interferon type i pathways in patients with covid-19: focusing on ages 1 to 90 years
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112317/
https://www.ncbi.nlm.nih.gov/pubmed/37072722
http://dx.doi.org/10.1186/s12879-023-08225-9
work_keys_str_mv AT abbasifardmitra evaluationoftheinteractionbetweentumorgrowthfactorbandinterferontypeipathwaysinpatientswithcovid19focusingonages1to90years
AT fakhrabadialihasani evaluationoftheinteractionbetweentumorgrowthfactorbandinterferontypeipathwaysinpatientswithcovid19focusingonages1to90years
AT bahremandfatemeh evaluationoftheinteractionbetweentumorgrowthfactorbandinterferontypeipathwaysinpatientswithcovid19focusingonages1to90years
AT khorramdelazadhossein evaluationoftheinteractionbetweentumorgrowthfactorbandinterferontypeipathwaysinpatientswithcovid19focusingonages1to90years